AMENDMENT #2 TO THE RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • March 5th, 2019 • Ziopharm Oncology Inc • Pharmaceutical preparations
This AMENDMENT #2 (“AMENDMENT #2”) to the RESEARCH AND DEVELOPMENT AGREEMENT (the “AGREEMENT”) is entered into as of January 17, 2017 by and among THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“UTMDACC”), INTREXON CORPORATION (“INTREXON”) and ZIOPHARM ONCOLOGY, INC. (“ZIOPHARM”). Capitalized terms used herein and not defined shall have the meaning ascribed to them in the AGREEMENT.
AMENDMENT #1 TO RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • March 5th, 2019 • Ziopharm Oncology Inc • Pharmaceutical preparations
This AMENDMENT #1 (“AMENDMENT #1”) to the RESEARCH AND DEVELOPMENT AGREEMENT (the “AGREEMENT”) is effective upon execution of the NEW RESEARCH PROGRAM by and among THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“UTMDACC”), INTREXON CORPORATION (“INTREXON”) and ZIOPHARM ONCOLOGY, INC. (“ZIOPHARM”). Capitalized terms used herein and not defined shall have the meaning ascribed to them in the AGREEMENT.
AMENDMENT #3 TO THE RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • March 5th, 2019 • Ziopharm Oncology Inc • Pharmaceutical preparations
This AMENDMENT #3 (“AMENDMENT #3”) to the RESEARCH AND DEVELOPMENT AGREEMENT, AMENDMENT #1, and AMENDMENT #2 (collectively, the “AGREEMENT”) is entered into as of November 14, 2017 by and among THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“UTMDACC”), INTREXON CORPORATION (“INTREXON”) and ZIOPHARM ONCOLOGY, INC. (“ZIOPHARM”). Capitalized terms used herein and not defined shall have the meaning ascribed to them in the AGREEMENT.
